Skip to main content
Jeffrey Yap

Jeffrey Yap, PhD

Languages spoken: English

Jeffrey Yap, PhD, is a research professor in the Department of Radiology and Imaging Sciences at the University of Utah. He is also the Director of the Center for Quantitative Cancer Imaging and a member of the Experimental Therapeutics Program at the Huntsman Cancer Institute. Dr. Yap's research interest is in the use of quantitative multimodality imaging to develop and evaluate novel cancer therapy in murine tumor models and cancer clinical trials. Dr. Yap received a Bachelor's of Science in Physics at the University of Dallas and a PhD in Medical Physics at the Unverisity of Chicago.

Education History

Doctoral Training University of Chicago, Departments of Radiology and Radiation & Cellular Oncology
University of Dallas

Selected Publications

Journal Article

  1. Saffari HPeterson KA, Leiferman KM, Stabin MG, Krstyen JJ, Clayton FC, Pease LF IIIYap JTHoffman JM, Gleich GJ (In press, 2019). Oral Administration of 99mTechnetium-Labelled Heparin in Eosinophilic Esophagitis. (Epub ahead of print) Mayo Clin Proc.
  2. Mihalopoulos NL, Yap JT, Holubkov R, Balch A, Hoffman JM (In press, 1/2020). Metabolically Active Brown Adipose Tissue Lowers Metabolic Dysfunction Among Obese and Morbidly Obese Young Adults. (Epub ahead of print)
  3. Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal R, Porretta J, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol.
  4. Silvis MR, Silva D, Rohweder R, Schuman S, Gudipaty S, Truong A, Yap J, Affolter K, McMahon M, Kinsey C (2023). MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. J Exp Med, 220(3).
  5. Mihalopoulos NL, Yap JT, Beardmore B, Holubkov R, Nanjee MN, Hoffman JM (2020). Cold-Activated Brown Adipose Tissue is Associated with Less Cardiometabolic Dysfunction in Young Adults with Obesity. Obesity (Silver Spring), 28(5), 916-923.
  6. von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD (2019). Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res, 26(8), 1837-1845.
  7. Saffari H, Peterson KA, Leiferman KM, Stabin MG, Krstyen JJ, Clayton FC, Pease LF 3rd, Yap JT, Hoffman JM, Gleich GJ (2019). Oral Administration of 99mTechnetium-Labeled Heparin in Eosinophilic Esophagitis. Mayo Clin Proc, 95(3), 449-458.
  8. Swami U, Yap JT, Agarwal N (2019). Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. JAMA Oncol, 6(2), 225-226.
  9. Abbott D, OBrien S, Farnham JM, Young EL, Yap J, Jones K, Lessnick SL, Randall RL, Schiffman JD, Cannon-Albright LA (2019). Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer Med, 8(18), 7924-7930.
  10. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 25(4), 620-627.
  11. Wang LM, Wu Q, Kirk RA, Horn KP, Ebada Salem AH, Hoffman JM, Yap JT, Sonnen JA, Towner RA, Bozza FA, Rodrigues RS, Morton KA (2018). Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain. Am J Nucl Med Mol Imaging, 8(2), 86-99.
  12. Karsy M, Gillespie DL, Horn KP, Burrell LD, Yap JT, Jensen RL (2018). Correlation of Glioma Proliferation and Hypoxia by Luciferase, Magnetic Resonance, and Positron Emission Tomography Imaging. Methods Mol Biol, 1742, 301-320.
  13. Barrott JJ, Zhu JF, Smith-Fry K, Susko AM, Nollner D, Burrell LD, Pozner A, Capecchi MR, Yap JT, Cannon-Albright LA, Deng X, Jones KB (2017). The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis. Mol Cancer Res, 15(12), 1733-1740.
  14. Qin L, Schwartzman A, McCall K, Kachouie NN, Yap JT (2017). Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials. J Med Imaging (Bellingham), 4(2), 024006.
  15. ONeill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT (2016). Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol, 130(3), 495-503.
  16. Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S (2016). Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol, 27(9), 1794-9.
  17. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15(1), 15.
  18. Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD (2015). Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol, 33(24), 2623-31.
  19. Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS (2015). Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials. J Nucl Med, 56(6), 955-61.
  20. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME (2015). A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer, 13(2), 113-23.
  21. Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, ODay S, Kim K, Hodi FS, Van den Abbeele AD (2014). Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging, 14, 30.
  22. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res, 2(7), 632-42.
  23. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL (2014). Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 32(12), 1202-9.
  24. Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman A (2014). Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat, 3(1), 172-186.
  25. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, ODay SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE (2013). Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol, 31(26), 3182-90.
  26. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD (2012). Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol, 30(19), 2401-7.
  27. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood, 119(20), 4597-607.
  28. Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA (2012). ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med, 53(4), 567-74.
  29. Aristophanous M, Yong Y, Yap JT, Killoran JH, Allen AM, Berbeco RI, Chen AB (2012). Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. Radiother Oncol, 102(3), 377-82.
  30. Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB (2012). Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys, 82(1), e99-105.
  31. Aristophanous M, Yap JT, Killoran JH, Chen AB, Berbeco RI (2011). Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions. Int J Radiat Oncol Biol Phys, 80(3), 900-8.
  32. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK (2011). Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol, 59(5), 856-62.
  33. Balter JM, Haffty BG, Dunnick NR, Siegel EL, Balter J, Dunnick NR, Haffty B, Siegel E, Palta J, Hahn S, Cao Y, Bentzen S, Van den Abbeele A, Luker G, Michalski J, Galvin J, Khoo V, Alber M, Low D, Mageras G, Atcher R, Yap J, Jeraj R, Jackson E, Wahl R, Deye J, Clarke L, Vikram B, Stone H, Wong R, Croft B, Farahani K, Kelloff G, Shankar L (2011). Imaging opportunities in radiation oncology. Int J Radiat Oncol Biol Phys, 79(2), 342-7.
  34. Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jnne PA, Van den Abbeele AD, Johnson BE (2011). CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol, 18(1), 54-62.
  35. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Janne PA, Johnson BE, Van den Abbeele AD (2010). New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol, 195(3), W221-8.
  36. Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR (2009). Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol, 193(2), 326-32.
  37. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, OMara MM, DAdamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML (2009). Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol, 27(19), 3154-60.
  38. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ (2009). Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology. Clin Cancer Res, 15(6), 1891-7.
  39. Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC (2008). Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res, 14(8), 2387-95.
  40. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008). F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA, 299(11), 1315-9.
  41. Laforest R, Longford D, Siegel S, Newport DF, Yap J (2007). Performance Evaluation of the microPET®—FOCUS-F120. IEEE Trans Nucl Sci, 54(1), 42-49.
  42. Wall JS, Kennel SJ, Paulus M, Gregor J, Richey T, Avenell J, Yap J, Townsend D, Weiss DT, Solomon A (2006). Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med, 47(12), 2016-24.
  43. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D, National Cancer Institute (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med, 47(6), 1059-66.
  44. Yap JT, Carney JP, Hall NC, Townsend DW (2004). Image-guided cancer therapy using PET/CT. Cancer J, 10(4), 221-33.
  45. Carney JPJ, Yap JT, Townsend DW (2004). PET count rate performance and CT image quality of a 16-slice LSO PET/CT for clinical whole-body imaging. Radiat Phys Chem Oxf Engl 1993, (71), 963-965.
  46. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol, 21(15), 2823-30.
  47. Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL (2003). Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer, 89(2), 262-7.
  48. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye EO (2000). Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet, 355(9221), 2125-31.
  49. Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham VJ (2000). A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med, 41(4), 706-11.
  50. Gunn RN, Ranicar A, Yap JT, Wells P, Osman S, Jones T, Cunningham VJ (2000). On-line measurement of exhaled [11C]CO2 during PET. J Nucl Med, 41(4), 605-11.
  51. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG (1999). Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med, 40(11), 1848-56.


  1. Karsy M, Gillespie DL, Horn K, Harper J, Ruesch M, Yap JT, Jensen RL (2018). MRI of Hypoxia in Primary Central Nervous System Tumors: Part II. [Review]. Contemp Neurosurg, 40(13), 1-8.
  2. Townsend DW, Carney JP, Yap JT, Hall NC (2004). PET/CT today and tomorrow. [Review]. J Nucl Med, 45 Suppl 1, 4S-14S.

Book Chapter

  1. Yap JT, Townsend DW, Hall NC (2005). Chapter 8: PET/CT in IMRT Planning. In Decker BC (Ed.), Intensity modulated radiation therapy: A clinical perspective (pp. 115-130). Hamilton.